Emergent Biosolutions (EBS) 30.80 $EBS
Glancy Prongay & Murray Commences Investigation on Behalf of Emergent BioSolutions, Inc. Investors
BusinessWire - Thu Aug 04, 9:30AM CDT
Glancy Prongay & Murray LLP ("GPM"
announces an investigation on behalf of investors of Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS) concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
EBS: 30.80 (+0.38)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Emergent Biosolutions, Inc. (EBS) & Lead Plaintiff Deadline: September 19, 2016
ACCESSWIRE - Thu Aug 04, 9:24AM CDT
NEW YORK, NY / ACCESSWIRE / August 4, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court District of Maryland on behalf of those who purchased shares of Emergent Biosolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS) during the period between January 11, 2016 and June 21, 2016, inclusive (the "Class Period".
EBS: 30.80 (+0.38)
SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE - Tue Aug 02, 10:29AM CDT
IRVINE, CA / ACCESSWIRE / August 2, 2016 / Khang & Khang LLP (the "Firm" announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.
EBS: 30.80 (+0.38)
Lifshitz & Miller Law Firm Announces Investigation of Ambac Financial Group, Inc., CBL & Associates Properties Inc., Emergent BioSolutions, Inc., Insmed Incorporated, K12 Inc., Lipocine, Inc., and Stericycle, Inc.
PR Newswire - Tue Aug 02, 6:31AM CDT
ATTORNEY ADVERTISING --
INSM: 11.84 (+0.09), EBS: 30.80 (+0.38), AMBC: 18.20 (-0.04), CBL: 12.08 (+0.30), SRCL: 87.79 (-0.20), LPCN: 3.59 (unch), LRN: 12.55 (-0.24)
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. And Encourages Investors with Losses to Contact the Firm
ACCESSWIRE - Mon Aug 01, 10:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 1, 2016 / Lundin Law PC (the "Firm" announces a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS) concerning possible violations of federal securities laws between January 11, 2016 and June 21, 2016 (the "Class Period". Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm before the September 19, 2016 lead plaintiff motion deadline.
EBS: 30.80 (+0.38)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 19, 2016 -- EBS
Marketwired - Mon Aug 01, 10:13AM CDT
NEW YORK, NY--(Marketwired - August 01, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EBS: 30.80 (+0.38)
IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE - Mon Aug 01, 10:04AM CDT
IRVINE, CA / ACCESSWIRE / August 1, 2016 / Khang & Khang LLP (the "Firm" announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.
EBS: 30.80 (+0.38)
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics
GlobeNewswire - Mon Aug 01, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through the distribution of all of the shares of Aptevo common stock to the holders of Emergent BioSolutions common stock. As a result of the spin-off, Aptevo is now an independent public company and listed on the Nasdaq Global Select Market under the ticker symbol "APVO."
EBS: 30.80 (+0.38), APVO: 3.06 (+0.12)
Aptevo Therapeutics Completes Separation from Emergent BioSolutions
BusinessWire - Mon Aug 01, 6:00AM CDT
Aptevo Therapeutics Inc. ("Aptevo" (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the completion of its separation from Emergent BioSolutions Inc. ("Emergent" (NYSE: EBS) and its launch as an independent, publicly traded corporation. Aptevo common stock will begin "regular way" trading under the symbol "APVO" on the Nasdaq Global Select Market today, August 1, 2016.
EBS: 30.80 (+0.38), APVO: 3.06 (+0.12)
EMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS
Marketwire Canada - Fri Jul 29, 9:07PM CDT
NEW ORLEANS, LA--(Marketwired - July 29, 2016) - Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions, Inc. (NYSE: EBS), if they purchased the Company's securities between January 11, 2016 and June 21, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the District of Maryland.
EBS: 30.80 (+0.38)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.
GlobeNewswire - Fri Jul 29, 2:19PM CDT
Rigrodsky & Long, P.A.:
EBS: 30.80 (+0.38)
SHAREHOLDER ALERT: Rosen Law Firm Reminds Emergent BioSolutions, Inc. Investors of Important Deadline in Class Action
BusinessWire - Fri Jul 29, 1:26PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Emergent BioSolutions, Inc. common stock (NYSE:EBS) from January 11, 2016 through June 21, 2016, both dates inclusive (the "Class Period" of the important September 19, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Emergent BioSolutions investors under the federal securities laws.
EBS: 30.80 (+0.38)
SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Fri Jul 29, 11:21AM CDT
Goldberg Law PC (the "Firm" announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 (the "Class Period" are encouraged to contact the Firm in advance of the September 19, 2016 lead plaintiff motion deadline.
EBS: 30.80 (+0.38)
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Emergent Biosolutions, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
BusinessWire - Fri Jul 29, 10:14AM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland, Southern Division, on behalf of purchasers of Emergent Biosolutions, Inc. (NYSE: EBS) ("Emergent" or the "Company" common stock during the period between January 11, 2016 and June 21, 2016, inclusive (the "Class Period". Emergent is headquartered in Gaithersburg, Maryland. Brower Piven is the only firm headquartered in Maryland with a practice dedicated primarily to shareholder class action litigation.
EBS: 30.80 (+0.38)
Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement
GlobeNewswire - Fri Jul 15, 12:17PM CDT
-- Aptevo Therapeutics common stock approved for listing on the NASDAQ Global Select Market
EBS: 30.80 (+0.38)
Should You Get Rid of Emergent BioSolutions (EBS) Now?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 7:35AM CDT
One stock that you may want to consider dropping is Emergent BioSolutions (EBS), which has witnessed a significant price decline in the past four weeks
EBS: 30.80 (+0.38), ENZ: 6.70 (-0.05)
Emergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock
GlobeNewswire - Fri Jul 15, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company's management to implement a stock repurchase program for up to $50 million of the company's common stock from time to time on the open market or in privately negotiated transactions.
EBS: 30.80 (+0.38)
Ligand (LGND) Signs Deal with Gilead for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 10:00AM CDT
Ligand (LGND) announced that it has entered into a worldwide license agreement with Gilead (GILD) for OmniAb Technology.
EBS: 30.80 (+0.38), INVA: 12.86 (-0.15), GILD: 79.78 (-0.31), LGND: 133.13 (-0.01)
Glancy Prongay & Murray Commences Investigation on Behalf of Emergent BioSolutions, Inc. Investors
BusinessWire - Thu Aug 04, 9:30AM CDT
Glancy Prongay & Murray LLP ("GPM"
announces an investigation on behalf of investors of Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS) concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors. EBS: 30.80 (+0.38)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Emergent Biosolutions, Inc. (EBS) & Lead Plaintiff Deadline: September 19, 2016
ACCESSWIRE - Thu Aug 04, 9:24AM CDT
NEW YORK, NY / ACCESSWIRE / August 4, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court District of Maryland on behalf of those who purchased shares of Emergent Biosolutions, Inc. ("Emergent" or the "Company"
(NYSE: EBS) during the period between January 11, 2016 and June 21, 2016, inclusive (the "Class Period". EBS: 30.80 (+0.38)
SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE - Tue Aug 02, 10:29AM CDT
IRVINE, CA / ACCESSWIRE / August 2, 2016 / Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline. EBS: 30.80 (+0.38)
Lifshitz & Miller Law Firm Announces Investigation of Ambac Financial Group, Inc., CBL & Associates Properties Inc., Emergent BioSolutions, Inc., Insmed Incorporated, K12 Inc., Lipocine, Inc., and Stericycle, Inc.
PR Newswire - Tue Aug 02, 6:31AM CDT
ATTORNEY ADVERTISING --
INSM: 11.84 (+0.09), EBS: 30.80 (+0.38), AMBC: 18.20 (-0.04), CBL: 12.08 (+0.30), SRCL: 87.79 (-0.20), LPCN: 3.59 (unch), LRN: 12.55 (-0.24)
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. And Encourages Investors with Losses to Contact the Firm
ACCESSWIRE - Mon Aug 01, 10:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 1, 2016 / Lundin Law PC (the "Firm"
announces a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS) concerning possible violations of federal securities laws between January 11, 2016 and June 21, 2016 (the "Class Period". Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm before the September 19, 2016 lead plaintiff motion deadline. EBS: 30.80 (+0.38)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 19, 2016 -- EBS
Marketwired - Mon Aug 01, 10:13AM CDT
NEW YORK, NY--(Marketwired - August 01, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EBS: 30.80 (+0.38)
IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE - Mon Aug 01, 10:04AM CDT
IRVINE, CA / ACCESSWIRE / August 1, 2016 / Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline. EBS: 30.80 (+0.38)
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics
GlobeNewswire - Mon Aug 01, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through the distribution of all of the shares of Aptevo common stock to the holders of Emergent BioSolutions common stock. As a result of the spin-off, Aptevo is now an independent public company and listed on the Nasdaq Global Select Market under the ticker symbol "APVO."
EBS: 30.80 (+0.38), APVO: 3.06 (+0.12)
Aptevo Therapeutics Completes Separation from Emergent BioSolutions
BusinessWire - Mon Aug 01, 6:00AM CDT
Aptevo Therapeutics Inc. ("Aptevo"
(Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the completion of its separation from Emergent BioSolutions Inc. ("Emergent" (NYSE: EBS) and its launch as an independent, publicly traded corporation. Aptevo common stock will begin "regular way" trading under the symbol "APVO" on the Nasdaq Global Select Market today, August 1, 2016. EBS: 30.80 (+0.38), APVO: 3.06 (+0.12)
EMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS
Marketwire Canada - Fri Jul 29, 9:07PM CDT
NEW ORLEANS, LA--(Marketwired - July 29, 2016) - Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions, Inc. (NYSE: EBS), if they purchased the Company's securities between January 11, 2016 and June 21, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the District of Maryland. EBS: 30.80 (+0.38)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.
GlobeNewswire - Fri Jul 29, 2:19PM CDT
Rigrodsky & Long, P.A.:
EBS: 30.80 (+0.38)
SHAREHOLDER ALERT: Rosen Law Firm Reminds Emergent BioSolutions, Inc. Investors of Important Deadline in Class Action
BusinessWire - Fri Jul 29, 1:26PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Emergent BioSolutions, Inc. common stock (NYSE:EBS) from January 11, 2016 through June 21, 2016, both dates inclusive (the "Class Period"
of the important September 19, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Emergent BioSolutions investors under the federal securities laws. EBS: 30.80 (+0.38)
SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Fri Jul 29, 11:21AM CDT
Goldberg Law PC (the "Firm"
announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company" (NYSE: EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 (the "Class Period" are encouraged to contact the Firm in advance of the September 19, 2016 lead plaintiff motion deadline. EBS: 30.80 (+0.38)
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Emergent Biosolutions, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
BusinessWire - Fri Jul 29, 10:14AM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland, Southern Division, on behalf of purchasers of Emergent Biosolutions, Inc. (NYSE: EBS) ("Emergent" or the "Company"
common stock during the period between January 11, 2016 and June 21, 2016, inclusive (the "Class Period". Emergent is headquartered in Gaithersburg, Maryland. Brower Piven is the only firm headquartered in Maryland with a practice dedicated primarily to shareholder class action litigation. EBS: 30.80 (+0.38)
Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement
GlobeNewswire - Fri Jul 15, 12:17PM CDT
-- Aptevo Therapeutics common stock approved for listing on the NASDAQ Global Select Market
EBS: 30.80 (+0.38)
Should You Get Rid of Emergent BioSolutions (EBS) Now?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 7:35AM CDT
One stock that you may want to consider dropping is Emergent BioSolutions (EBS), which has witnessed a significant price decline in the past four weeks
EBS: 30.80 (+0.38), ENZ: 6.70 (-0.05)
Emergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock
GlobeNewswire - Fri Jul 15, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company's management to implement a stock repurchase program for up to $50 million of the company's common stock from time to time on the open market or in privately negotiated transactions.
EBS: 30.80 (+0.38)
Ligand (LGND) Signs Deal with Gilead for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 10:00AM CDT
Ligand (LGND) announced that it has entered into a worldwide license agreement with Gilead (GILD) for OmniAb Technology.
EBS: 30.80 (+0.38), INVA: 12.86 (-0.15), GILD: 79.78 (-0.31), LGND: 133.13 (-0.01)
